Results 61 to 70 of about 75,992 (272)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab

Thoracic Cancer, 2019
Background It remains unclear why radiation clinically provides a synergistic effect when combined with immune checkpoint inhibitors such as nivolumab. The purpose of our study was to retrospectively evaluate whether the therapeutic efficacy of nivolumab
Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, Atsuto Mouri, Yu Miura, Ayako Shiono, Fuyumi Nishihara, Yoshitake Murayama, Shin‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu   +11 more
doaj   +1 more source

CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer [PDF]

, 2018
Purpose: Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction ...
Tschaika, Marina, Peltola, Katriina, C. Harbison, Harbison, Christopher T., de Braud, Filippo, P. Sharma, P. Ott, Bendell, Johanna, E. Calvo, Janjigian, Yelena Y., P. Ascierto, D. Le, F. de Braud, Sharma, Padmanee, K. Peltola, Calvo, Emiliano, Jaeger, Dirk, Evans, Jeffry, Kim, Joseph W., Chau, Ian, D. Jaeger, J. Kim, J. Evans, C. Dorange, J. Bendell, Le, Dung T., Y. Janjigian, M. Tschaika, Ascierto, Paolo A., Ott, Patrick A., I. Chau, Dorange, Cecile   +31 more
core   +1 more source

Advances in Gastric Cancer Research: Insights Into Carcinogenesis, the Tumor Microenvironment, Metastasis, and Factors Influencing Prognosis

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background The Department of Gastroenterological Surgery at Kumamoto University has maintained a commitment to integrating cutting‐edge clinical practice with fundamental research, particularly concerning malignant diseases of the digestive tract.
Hideo Baba, Takatsugu Ishimoto, Yoshifumi Baba, Hiromitsu Hayashi, Masaaki Iwatsuki   +4 more
wiley   +1 more source

Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081

Journal for ImmunoTherapy of Cancer
Background For unresectable stage III non-small-cell lung cancer (NSCLC), the optimal duration and regimen of consolidation immunotherapy following chemoradiation is unknown.
Borys Hrinczenko, Jarushka Naidoo, Jason Chesney, Salma K Jabbour, Naomi Fujioka, Greg Durm, Apar Kishor Ganti, Hirva Mamdani, Mary Jo Fidler, Nasser H Hanna, Shadia Jalal, Ticiana A Leal, Sandra Althouse, Susan Perkins, Lawrence Feldman   +14 more
doaj   +1 more source

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer

OncoImmunology, 2017
Nivolumab, an anti PD-1 checkpoint inhibitor has demonstrated efficacy in metastatic non-small-cell lung cancer (NSCLC) patients after failure to standard chemotherapy. Standard chemotherapy agents could promote antitumor immune response.
Courèche-Guillaume Kaderbhai, Corentin Richard, Jean David Fumet, Anne Aarnink, Sandra Ortiz-Cuaran, Maurice Pérol, Pascal Foucher, Bruno Coudert, Laure Favier, Aurélie Lagrange, Emeric Limagne, Romain Boidot, Sylvain Ladoire, Michel Poudenx, Marius Ilie, Paul Hofman, Pierre Saintigny, François Ghiringhelli   +17 more
doaj   +1 more source

Nivolumab – Pearls of evidence

Indian Journal of Medical and Paediatric Oncology, 2017
Nivolumab is one of the most extensively studied immune checkpoint inhibitors across various tumor types. In this narrative review, the current clinical efficacy and safety data of anti-programmed death-1 (PD-1) nivolumab for nonsmall cell lung cancer (NSCLC) and renal cell cancer (RCC) are elucidated.Systematic search was done on Pubmed, Medline ...
openaire   +2 more sources

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma

Hepatology Communications, 2020
Regorafenib and nivolumab are drugs approved for second‐line treatment of patients with hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of regorafenib and nivolumab following sorafenib has not been directly compared ...
Won‐Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Young‐Hwa Chung, Young‐Sang Lee, Sook Ryun Park, Min‐Hee Ryu, Baek‐Yeol Ryoo, So Jung Lee, Kang Mo Kim   +12 more
doaj   +1 more source

Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report

Surgical Case Reports, 2020
Background The prognosis of patients with recurrent gastric cancer is poor despite chemotherapy being clinically recommended as the first therapeutic strategy.
Takaaki Arigami, Daisuke Matsushita, Keishi Okubo, Takako Tanaka, Ken Sasaki, Masahiro Noda, Yoshiaki Kita, Shinichiro Mori, Yusuke Tsuruda, Hiroshi Kurahara, Takao Ohtsuka   +10 more
doaj   +1 more source

Reassessing the cost-effectiveness of Nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price. [PDF]

, 2021
Aims: The aim of this study was to estimate the cost-effectiveness of nivolumab versus everolimus for second-line treatment of renal cell carcinoma (RCC) based on mature data, updated safety and decreased everolimus price.
Kim, H, Liew, Danny, Kim, Hansoo, Goodall, Stephen, Liew, D, Goodall, S   +5 more
core   +1 more source